Pochi studi hanno valutato la crescente utilità di più biomarcatori provenienti da diversi percorsi biologici nel predire il rischio di eventi cardiovascolari.
- Abbiamo misurato 10 biomarcatori su 3209 partecipanti al ciclo di routine Framingham Heart Study: livelli di proteina C-reattiva, peptide natriuretico di tipo B, peptide natriuretico proprietario N-terminale, aldosterone, renina, fibrinogeno, D-dimero, inibitore dell’attivatore del plasminogeno di tipo 1 e omocisteina; e il rapporto tra albumina urinaria e creatinina.
- Podczas obserwacji (mediana 7,4 roku) zmarło 207 uczestników, au 169 wystąpiło pierwsze poważne zdarzenie sercowo-naczyniowe. W modelach proporcjonalnych zagrożeń Coxa z uwzględnieniem konwencjonalnych czynników ryzyka, następujące biomarkery najsilniej przewidywały ryzyko zgonu (po każdym biomarkerze następuje skorygowany współczynnik ryzyka na przyrost o 1 SD w wartościach log): Poziom peptydu natriuretycznego typu B (1,40) ), poziom białka C-reaktywnego (1,39), stosunek albuminy do kreatyniny w moczu (1,22), poziom homocysteiny (1,20) i poziom reniny (1,17).
- Biomarkerami, które najsilniej przewidywały poważne zdarzenia sercowo-naczyniowe, były poziom peptydów natriuretycznych typu B (skorygowany współczynnik ryzyka, 1,25 na przyrost 1 SD w wartościach log) oraz stosunek albuminy w moczu do kreatyniny (1,20). Osoby z punktacją „ multimarker ” (na podstawie współczynników regresji istotnych biomarkerów) w najwyższym kwintylu w porównaniu z osobami z wynikami w dwóch najniższych kwintylach miały podwyższone ryzyko zgonu (skorygowany współczynnik ryzyka, 4,08; p<0,001) i poważne zdarzenia sercowo-naczyniowe (skorygowany współczynnik ryzyka 1,84; P=0,02). Jednak dodanie wyników wielomarkerowych do konwencjonalnych czynników ryzyka spowodowało jedynie niewielki wzrost zdolności do klasyfikowania ryzyka, mierzonego statystyką C.
- Do oceny ryzyka u poszczególnych osób zastosowanie 10 współczesnych biomarkerów, które badaliśmy, dodaje tylko umiarkowanie do standardowych czynników ryzyka
Efficienza e potenza in genetica.
Abbiamo esaminato la selezione e l’analisi dei marcatori SNP per studi di associazione sull’intero genoma, esaminando in dettaglio la relazione tra investimento di genotipizzazione e potenza statistica. I metodi pairwise o multimarker massimizzano l’efficienza e la potenza? Quanta potenza è a rischio quando i tag vengono selezionati da una risorsa incompleta come HapMap? Abbiamo risposto a queste domande utilizzando i dati genotipici del progetto HapMap ENCODE, studi di associazione simulati in un modello di malattia realistico e aggiustamenti empirici per testare ipotesi multiple.Mostriamo un metodo di tagging basato sull’aplotipo che supera in modo uniforme i metodi di test e definizione delle priorità dei singoli marker che migliorano notevolmente l’efficienza di tagging. Testare tutti gli aplotipi osservati per l’associazione, non solo quelli che sono controparti di SNP noti, aumenta la capacità di rilevare alleli causali rari a scapito della potenza ridotta per rilevare alleli causali comuni. La potenza resiste alla completezza del pannello di riferimento da cui vengono selezionati i marker. Questi risultati sono importanti per dare priorità ai marcatori SNP e interpretare gli studi di associazione.
Analisi avanzata di un insieme di SNP di associazione dell’ampio genoma per il controllo dei casi.
- GWAS è diventato uno strumento popolare per identificare le varianti genetiche associate al rischio di malattia. L’analisi dei casi di controllo GWAS standard include una valutazione dell’associazione tra ogni singolo SNP genotipizzato e il rischio di malattia.
- Questo approccio, tuttavia, ha una riproducibilità limitata e difficoltà nel rilevare effetti multi-SNP ed epistatici. Come strategia analitica alternativa, proponiamo di raggruppare gli SNP in insiemi di SNP in base alla vicinanza di caratteristiche genomiche come geni o blocchi di aplotipi e quindi testare l’effetto comune di ciascun insieme di SNP.
- Il test di ogni set di SNP viene eseguito con un test logistico basato sulla macchina del kernel che si basa su statistiche che consentono una modellazione flessibile degli effetti SNP epistatici e non lineari. Questa flessibilità e la capacità di adattarsi naturalmente agli effetti covariati sono caratteristiche importanti del nostro test che lo rendono interessante rispetto ai test SNP individuali e ai test multimarcatori esistenti .
- Utilizzando dati simulati basati sul progetto internazionale HapMap, dimostriamo che testare un insieme di SNP può essere più potente rispetto all’analisi standard di singoli SNP su un’ampia gamma di impostazioni.
- In particolare, troviamo che il nostro approccio è più potente dell’analisi di singoli SNP quando la correlazione mediana tra la variante di suscettibilità alla malattia e gli SNP genotipizzati è da moderata ad alta. Quando la correlazione è bassa, sia l’analisi dei singoli SNP che l’analisi di un insieme di SNP sono generalmente a bassa potenza. Usiamo l’analisi del set SNP per analizzare i dati GWAS Discovery Phase (CGEMS) del cancro al seno.
Associazione ampia del genoma per la schizofrenia in CATIE: risultati dello stadio 1.
- Poco si sa con certezza sulla genetica della schizofrenia. L’emergere di associazioni a livello di genoma è stato ampiamente previsto come un modo promettente per identificare la variazione ripetitiva della sequenza del DNA associata a questo disturbo importante e devastante.
- Un totale di 738 casi di schizofrenia DSM-IV (tutti i partecipanti CATIE) e 733 gruppi di controllo abbinati sono stati genotipizzati per 492.900 polimorfismi a singolo nucleotide (SNP) utilizzando la piattaforma di genotipizzazione a doppio chip Affymetrix 500K e un’imbottitura personalizzata 164K. nel chip .
- Dopo più fasi di controllo della qualità sia per i soggetti che per gli SNP, sono state utilizzate analisi di regressione logistica per valutare l’evidenza di un’associazione di tutti gli SNP con la schizofrenia. Abbiamo identificato una serie di SNP promettenti per il follow-up, sebbene nessun SNP o combinazione di multimarcatori SNP abbia raggiunto una significatività statistica a livello di genoma.
- Sebbene diversi segnali coincidano con regioni del genoma precedentemente coinvolte nella schizofrenia, una coincidenza non può essere esclusa. Questi dati non forniscono prove del coinvolgimento di alcuna regione genomica nella schizofrenia rilevabile alla dimensione media del campione.
SITVITWEB – un database internazionale pubblicamente accessibile di multimarcatori per lo studio della diversità genetica e dell’epidemiologia molecolare del Mycobacterium tuberculosis.
- Tra i vari metodi di genotipizzazione per lo studio del polimorfismo genotipico del Mycobacterium tuberculosis complex (MTC), dello spoligotyping e delle unità ripetute intervallate da micobatteri, il numero variabile di ripetizioni di DNA in tandem (MIRU-VNTR) ha recentemente ottenuto l’approvazione internazionale come strumento robusto, veloce e riproducibile metodo di digitazione che genera dati in un formato portatile.
- Lo spoligotyping era la spina dorsale del database SpolDB4 pubblicamente disponibile rilasciato nel 2006; tuttavia, questo metodo ha un basso potere discriminante se usato da solo e dovrebbe idealmente essere utilizzato insieme a un secondo metodo di tipizzazione come MIRU-VNTR per studi epidemiologici ad alta risoluzione.
- Niniejszym opisujemy publicznie dostępną międzynarodową bazę danych o nazwie SITVITWEB, która zawiera takie dane wielomarkerowe , które pozwalają uzyskać globalną wizję różnorodności genetycznej MTC na całym świecie, opartą na 62 582 izolatach klinicznych odpowiadających 153 krajom pochodzenia pacjentów (105 krajów izolacji).
- Przedstawiamy łącznie 7105 wzorów spoligotypów (odpowiadających 58 180 izolatom klinicznym) – pogrupowanych na 2740 wspólnych typów lub międzynarodowych typów spoligotypów (SIT) zawierających 53 816 izolatów klinicznych i 4364 wzory sieroce.
- Co ciekawe, tylko 7% izolatów MTC na całym świecie było sierotami, podczas gdy ponad połowa izolatów poddanych SIT (n=27059) była ograniczona tylko do 24 najbardziej rozpowszechnionych SIT. Baza danych zawiera również łącznie 2379 wzorów MIRU (z 8161 izolatów klinicznych) z 87 krajów pochodzenia pacjentów (35 krajów izolacji); zostały one pogrupowane w 847 wspólnych typów lub
- Międzynarodowe typy MIRU (MIT) zawierające 6626 izolatów i 1533 wzory sieroce. Wreszcie, dane dotyczące dokładnych powtórzeń tandemowych (ETR) w 5 locus były dostępne dla 4626 izolatów z 59 krajów pochodzenia pacjentów (22 kraje izolacji); zaobserwowano łącznie 458 różnych wzorców VNTR – podzielonych na 245 wspólnych typów lub VNTR International Types (VIT) zawierających 4413 izolatów) i 213 wzorców sierocych.
- Eksploracja danych w SITVITWEB umożliwiła ponadto aktualizację zasad definiujących linie genotypowe MTC, a także uzyskanie nowego wglądu w strukturę populacji MTC i rozmieszczenie na świecie na poziomie krajowym, subregionalnym i kontynentalnym.
- Na poziomie ewolucyjnym zebrane dane mogą być przydatne do rozróżnienia okazjonalnej zbieżnej ewolucji genotypów od specyficznej ewolucji podlinii, na które zasadniczo wpływa adaptacja do gospodarza.
Tissue, Array, Human Tumor, Different Types of Tumor, Multi, tissue IV (8), gallbladder, control, esophagus, control, stomach, control, lung, control (matched with Total RNA Northern Blot) (Paraffin) |
|||
MBS639509-5x5Arrays | MyBiosource | 5x5Arrays | 3465 EUR |
Tissue, Array, Human Tumor, Different Types of Tumor, Multi, tissue II (8), esophagus, control, stomach, control, colon, control, rectum, control (matched with Total RNA Northern Blot) (Paraffin) |
|||
MBS639676-5Arrays | MyBiosource | 5Arrays | 805 EUR |
Tissue, Array, Human Tumor, Different Types of Tumor, Multi, tissue II (8), esophagus, control, stomach, control, colon, control, rectum, control (matched with Total RNA Northern Blot) (Paraffin) |
|||
MBS639676-5x5Arrays | MyBiosource | 5x5Arrays | 3465 EUR |
Tissue, Array, Human Tumor, Different Types of Tumor, Multi, tissue V (8), small intestine, control, esophagus, control, thymoma, control, lung, control (matched with Total RNA Northern Blot) (Paraffin) |
|||
MBS639572-5Arrays | MyBiosource | 5Arrays | 805 EUR |
Tissue, Array, Human Tumor, Different Types of Tumor, Multi, tissue V (8), small intestine, control, esophagus, control, thymoma, control, lung, control (matched with Total RNA Northern Blot) (Paraffin) |
|||
MBS639572-5x5Arrays | MyBiosource | 5x5Arrays | 3465 EUR |
Tissue, Array, Human Tumor, Different Types of Tumor, Multi, tissue III (8), kidney, control, oschea/ureter, control, bladder, control, stomach, control (matched with Total RNA Northern Blot) (Paraffin) |
|||
MBS639689-5Arrays | MyBiosource | 5Arrays | 805 EUR |
Tissue, Array, Human Tumor, Different Types of Tumor, Multi, tissue III (8), kidney, control, oschea/ureter, control, bladder, control, stomach, control (matched with Total RNA Northern Blot) (Paraffin) |
|||
MBS639689-5x5Arrays | MyBiosource | 5x5Arrays | 3465 EUR |
Breast Panel Multi-Tumor control slides, set of 5 |
|||
TS901 | Innovex | Set of 5 | 145 EUR |
Breast Panel Multi-Tumor control slides, set of 25 |
|||
TS901-25 | Innovex | Set of 25 | 395 EUR |
Tissue, Array, Human Tumor, Different Types of Tumor, Multi, tissue VI (8), breast, control, uterus, control, teratoma/fallopian tube, control, ovary, control (matched with Total RNA Northern Blot) (Paraffin) |
|||
MBS639445-5Arrays | MyBiosource | 5Arrays | 805 EUR |
Tissue, Array, Human Tumor, Different Types of Tumor, Multi, tissue VI (8), breast, control, uterus, control, teratoma/fallopian tube, control, ovary, control (matched with Total RNA Northern Blot) (Paraffin) |
|||
MBS639445-5x5Arrays | MyBiosource | 5x5Arrays | 3465 EUR |
Multiple lymphoma tissue array with normal tissue as control |
|||
LM481c | TissueArray | each | 198 EUR |
Multiple cancer tissue array with matched or unmatched normal control |
|||
MC802 | TissueArray | each | 306 EUR |
Multiple pancreatic cancer with 4 normal tissues control from autopsy |
|||
PA481 | TissueArray | each | 138 EUR |
Multiple cervix cancer tissue array with normal tissue control from autopsy |
|||
CR483 | TissueArray | each | 198 EUR |
Multiple Kidney cancer tissue array with normal tissue control from autopsy |
|||
KD483 | TissueArray | each | 168 EUR |
Multiple skin cancer tissue array with 4 normal tissue control from autopsy |
|||
SK482 | TissueArray | each | 168 EUR |
Tissue, Array, Human Tumor, Different Types of Tumor, Multi, tissue I (5), colon, control, rectum, control, normal placenta (matched with mRNA blots) (Paraffin) |
|||
MBS639553-5Arrays | MyBiosource | 5Arrays | 765 EUR |
Tissue, Array, Human Tumor, Different Types of Tumor, Multi, tissue I (5), colon, control, rectum, control, normal placenta (matched with mRNA blots) (Paraffin) |
|||
MBS639553-5x5Arrays | MyBiosource | 5x5Arrays | 3300 EUR |
Tissue, Array, Human Tumor, Different Types of Tumor, Multi, tissue II (5), breast, control, uterus, control, normal placenta (matched with mRNA blots) (Paraffin) |
|||
MBS639454-5Arrays | MyBiosource | 5Arrays | 765 EUR |
Tissue, Array, Human Tumor, Different Types of Tumor, Multi, tissue II (5), breast, control, uterus, control, normal placenta (matched with mRNA blots) (Paraffin) |
|||
MBS639454-5x5Arrays | MyBiosource | 5x5Arrays | 3300 EUR |
Tissue, Array, Human Tumor, Different Types of Tumor, Multi, tissue III (5), kidney, control, lung, control, normal placenta (matched with mRNA blots) (Paraffin) |
|||
MBS639459-5Arrays | MyBiosource | 5Arrays | 765 EUR |
Tissue, Array, Human Tumor, Different Types of Tumor, Multi, tissue III (5), kidney, control, lung, control, normal placenta (matched with mRNA blots) (Paraffin) |
|||
MBS639459-5x5Arrays | MyBiosource | 5x5Arrays | 3300 EUR |
Tissue, Array, Human Tumor, Different Types of Tumor, Multi, tissue VI (5), ovary, control, uterus, control, normal placenta (matched with mRNA blots) (Paraffin) |
|||
MBS639469-5Arrays | MyBiosource | 5Arrays | 765 EUR |
Tissue, Array, Human Tumor, Different Types of Tumor, Multi, tissue VI (5), ovary, control, uterus, control, normal placenta (matched with mRNA blots) (Paraffin) |
|||
MBS639469-5x5Arrays | MyBiosource | 5x5Arrays | 3300 EUR |
Tissue, Array, Human Tumor, Different Types of Tumor, Multi, tissue V (5), liver, control, stomach, control, normal placenta (matched with mRNA blots) (Paraffin) |
|||
MBS639388-5Arrays | MyBiosource | 5Arrays | 765 EUR |
Tissue, Array, Human Tumor, Different Types of Tumor, Multi, tissue V (5), liver, control, stomach, control, normal placenta (matched with mRNA blots) (Paraffin) |
|||
MBS639388-5x5Arrays | MyBiosource | 5x5Arrays | 3300 EUR |
Multi normal & tumor, 12 cases (1.5mm)HumanMulti-systemMulti-organsIHC control |
|||
MNT242 | Pantomics | 1.5mm | 50 EUR |
Multiple liver cancer tissue array with 4 normal tissues control from autopsy |
|||
LV482 | TissueArray | each | 168 EUR |
Tissue, Array, Human Tumor, Different Types of Tumor, Multi, tissue IV (5), bladder, control, esophagus, control, normal placenta (matched with mRNA blots) (Paraffin) |
|||
MBS639579-5Arrays | MyBiosource | 5Arrays | 765 EUR |
Tissue, Array, Human Tumor, Different Types of Tumor, Multi, tissue IV (5), bladder, control, esophagus, control, normal placenta (matched with mRNA blots) (Paraffin) |
|||
MBS639579-5x5Arrays | MyBiosource | 5x5Arrays | 3300 EUR |
Multiple cervix cancer tissue array with 4 normal tissues control from autopsy |
|||
CR482 | TissueArray | each | 198 EUR |
Rat Sodium-dependent Multi-Vitamin Transporter (SMVT) ), control/blocking peptide # 1 |
|||
SMVT11-P | Alpha Diagnostics | 100 ug | 196.8 EUR |
Multiple organ digestive system diseased tissue array with normal tissue as control |
|||
BCC000128 | TissueArray | each | 198 EUR |
Rat Pasteurella multocida Positive Control |
|||
MBS412069-1mL | MyBiosource | 1mL | 175 EUR |
Rat Pasteurella multocida Positive Control |
|||
MBS412069-5x1mL | MyBiosource | 5x1mL | 645 EUR |
Multiple parts of skin squamous cell carcinoma tissue array with normal tissues as control |
|||
SK483 | TissueArray | each | 168 EUR |
Mouse Pasteurella multocida Positive Control |
|||
MBS412066-1mL | MyBiosource | 1mL | 175 EUR |
Mouse Pasteurella multocida Positive Control |
|||
MBS412066-5x1mL | MyBiosource | 5x1mL | 645 EUR |
Rabbit Pasteurella Multocida Positive Control |
|||
MBS412028-1mL | MyBiosource | 1mL | 175 EUR |
Rabbit Pasteurella Multocida Positive Control |
|||
MBS412028-5x1mL | MyBiosource | 5x1mL | 645 EUR |
Multiple organ cancer tissue array with matched non-metastatic lymph node tissue as control |
|||
NMET961 | TissueArray | each | 204 EUR |
Mouse pasteurella multocida PCR Positive Control |
|||
MBS412577-025mL | MyBiosource | 0.25mL | 1500 EUR |
Mouse pasteurella multocida PCR Positive Control |
|||
MBS412577-5x025mL | MyBiosource | 5x0.25mL | 6545 EUR |
Multiple Tumor Tissue Array - 47 different tumors and their corresponding normal tissues, plus 2 control spots |
|||
T8235713-2 | Biochain | 2 slides | 430 EUR |
Multiple Tumor Tissue Array - 47 different tumors and their corresponding normal tissues, plus 2 control spots |
|||
T8235713-5 | Biochain | 5 slides | 1085 EUR |
Multiple Tumor Tissue Array - 12 types of human tissues in duplicates, designed as universal control for >90% routine IH |
|||
Z7020083 | Biochain | 5 slides | 321.6 EUR |
Multi-cable (for Controller & Chamber) |
|||
LBC12101 | Westburg | each | 503.58 EUR |
Natriuretic Peptide Receptor B / PGCB Western Blot Positive Control |
|||
MBS543115-5Applications | MyBiosource | 5Applications | 350 EUR |
Natriuretic Peptide Receptor B / PGCB Western Blot Positive Control |
|||
MBS543115-5x5Applications | MyBiosource | 5x5Applications | 1435 EUR |
Natriuretic Peptide Receptor C Antibody Western Blot Positive Control |
|||
MBS542999-5Applications | MyBiosource | 5Applications | 335 EUR |
Natriuretic Peptide Receptor C Antibody Western Blot Positive Control |
|||
MBS542999-5x5Applications | MyBiosource | 5x5Applications | 1350 EUR |
Natriuretic Peptide Receptor C / PGCC Antibody Western Blot Positive Control |
|||
MBS543116-5Applications | MyBiosource | 5Applications | 350 EUR |
Natriuretic Peptide Receptor C / PGCC Antibody Western Blot Positive Control |
|||
MBS543116-5x5Applications | MyBiosource | 5x5Applications | 1435 EUR |
Immortalized Multimammate Mouse Skin Keratinocytes (Kera5) |
|||
T0763 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
Pasteurella multocida Type IV fimbrial subunit protein (PTFA) control peptide |
|||
PTFA16-P | Alpha Diagnostics | 100 ug | 562.8 EUR |
NATtrol Norovirus Negative Control (6 x 0.125mL) |
|||
NATROTA-6MC | Zeptometrix | 6 x 0.125mL | 203 EUR |
NATtrol Candida/TV Positive Control (ea) |
|||
NATCTVPOS-BD | Zeptometrix | ea | 446 EUR |
NATtrol Parainfluenza Control (6 X 0.5mL) |
|||
NATPIV-ERC | Zeptometrix | 6 X 0.5mL | 265 EUR |
NATtrol BV Negative Control (6 X 0.15mL) |
|||
NATBVNEG-BD | Zeptometrix | 6 X 0.15mL | 295 EUR |
NATtrol BV Positive Control (6 X 0.15mL) |
|||
NATBVPOS-BD | Zeptometrix | 6 X 0.15mL | 446 EUR |
NATtrol RSV Positive Control (6 x 0.5mL) |
|||
NATRSV-6C | Zeptometrix | 6 x 0.5mL | 222 EUR |
NATtrol Norovirus GI Positive Control (6 x 0.125mL) |
|||
NATNOVI-6MC | Zeptometrix | 6 x 0.125mL | 205 EUR |
NATtrol AdV/hMPV/HRV Control (6 X 0.5mL) |
|||
NATAMR-ERC | Zeptometrix | 6 X 0.5mL | 227 EUR |
NATtrol Norovirus GII Positive Control (6 x 0.125mL) |
|||
NATNOVII-6MC | Zeptometrix | 6 x 0.125mL | 205 EUR |
NATtrol EV Negative Control (6 X 0.2 mL) |
|||
NATEVNEG-6MC | Zeptometrix | 6 X 0.2 mL | 208 EUR |
NATtrol EV Positive Control (6 X 0.2 mL) |
|||
NATEVPOS-6MC | Zeptometrix | 6 X 0.2 mL | 208 EUR |
NATtrol SA Positive Control (6 X 0.5 mL) |
|||
NATMSSA-6MC | Zeptometrix | 6 X 0.5 mL | 311 EUR |
NATtrol SA Positive Control (6 X 0.5 mL) |
|||
NATMSSA-6MC-IVD | Zeptometrix | 6 X 0.5 mL | 331 EUR |
NATtrol EV Positive Control (6 X 0.5 mL) |
|||
MDZ055 | Zeptometrix | 6 X 0.2 mL | 208 EUR |
NATtrol EV Negative Control (6 X 0.5 mL) |
|||
MDZ056 | Zeptometrix | 6 X 0.2 mL | 208 EUR |
NATtrol SA Positive Control (6 X 0.5 mL) |
|||
MDZ061 | Zeptometrix | 6 X 0.5 mL | 378.24 EUR |
Recombinant (E. coli) Purified Pasteurella multocida toxin (PMT) control for western blot |
|||
PMT11-C | Alpha Diagnostics | 100 ul | 343.2 EUR |
NATtrol MRSA Positive Control (6 x 0.35mL) |
|||
NATMRSA-6L | Zeptometrix | 6 x 0.35mL | 277 EUR |
Rat neurofascin (Nfasc)-control Control/blocking peptide |
|||
AB-23249-CP | Alpha Diagnostics | 100ug | 196.8 EUR |
AS Control |
|||
A26 | DataApex | - | 330 EUR |
GC Control |
|||
A23 | DataApex | - | 600 EUR |
LC Control |
|||
A24 | DataApex | - | 600 EUR |
NATtrol GBS Negative Control (6 X 0.5 mL) |
|||
NATLAC-6MC | Zeptometrix | 6 X 0.5 mL | 313 EUR |
NATtrol GBS Negative Control (6 X 0.5 mL) |
|||
NATLAC-6MC-IVD | Zeptometrix | 6 X 0.5 mL | 333 EUR |
NATtrol RSV Positive Control (6 X 0.5 mL) |
|||
NATRSV-6C-IVD | Zeptometrix | 6 X 0.5 mL | 242 EUR |
NATtrol GBS Positive Control (6 x 0.25 mL) |
|||
NATSAG-6L | Zeptometrix | 6 x 0.25 mL | 272 EUR |
NATtrol GBS Positive Control (6 X 0.5 mL) |
|||
NATSAG-6MC | Zeptometrix | 6 X 0.5 mL | 313 EUR |
NATtrol GBS Positive Control (6 x 0.5 mL) |
|||
NATSAG-6MC-IVD | Zeptometrix | 6 x 0.5 mL | 333 EUR |
NATtrol RSV Positive Control (6 X 0.5 mL) |
|||
MDZ047 | Zeptometrix | 6 X 0.5 mL | 278.4 EUR |
NATtrol GBS Positive Control (6 x 0.5 mL) |
|||
MDZ053 | Zeptometrix | 6 x 0.5 mL | 378.24 EUR |
NATtrol GBS Negative Control (6 X 0.5 mL) |
|||
MDZ054 | Zeptometrix | 6 X 0.5 mL | 378.24 EUR |
NATtrol EP Control (12 x 0.25 mL; 2 x 1mL) |
|||
NATEPC-NNS | Zeptometrix | 12 x 0.25 mL; 2 x 1mL | 452 EUR |
Rat Control |
|||
DEV99RC | Demeditec Diagnostics | 2 x 1 ml | 60 EUR |
MDP control |
|||
tlrl-mdpcl | InvivoGen FR | 5 mg | 148.05 EUR |
NATtrol MRSA Positive Control (6 X 0.5 mL) |
|||
NATMRSA-6MC | Zeptometrix | 6 X 0.5 mL | 315 EUR |
NATtrol MRSA Positive Control (6 X 0.5 mL) |
|||
NATMRSA-6MC-IVD | Zeptometrix | 6 X 0.5 mL | 335 EUR |
NATtrol MRSA Positive Control (6 X 0.5 mL) |
|||
MDZ059 | Zeptometrix | 6 X 0.5 mL | 378.24 EUR |
BMP4 Control |
|||
MBS542571-5Applications | MyBiosource | 5Applications | 335 EUR |
BMP4 Control |
|||
MBS542571-5x5Applications | MyBiosource | 5x5Applications | 1350 EUR |
Rat IgG-PE conjugate (isotype control) (Isotype control) |
|||
20005-PE | Alpha Diagnostics | 25 tests | 242.4 EUR |
NATtrol Norovirus GI/GII Positive Control (6 x 0.125mL) |
|||
NATNOV-6MC | Zeptometrix | 6 x 0.125mL | 205 EUR |
Rat IgG-HRP conjugate (isotype control) (Isotype control) |
|||
20005-HP | Alpha Diagnostics | 100 ug | 196.8 EUR |
NPY1R Control |
|||
MBS543000-5Applications | MyBiosource | 5Applications | 335 EUR |
ADCY3 Control |
|||
MBS543023-5Applications | MyBiosource | 5Applications | 335 EUR |
ADCY3 Control |
|||
MBS543023-5x5Applications | MyBiosource | 5x5Applications | 1350 EUR |
NPY1R Control |
|||
MBS543000-5x5Applications | MyBiosource | 5x5Applications | 1350 EUR |
pGIPZ control |
|||
PVTY00348 | Nova Lifetech | 2ug | 280 EUR |
pMD19- Control |
|||
PVT10564 | Nova Lifetech | 2ug | 182 EUR |
Rat IgG-FITC conjugate (isotype control) (Isotype control) |
|||
20005-F | Alpha Diagnostics | 100 ug | 196.8 EUR |
NATtrol CT/NG Negative Control (6 X 1 mL) |
|||
NATCT/NGNEG-6MC | Zeptometrix | 6 X 1 mL | 220 EUR |
Control Slides |
|||
24012-1 | Polysciences Europe GmbH | 1box | 78 EUR |
Canine Control |
|||
DEV99CC | Demeditec Diagnostics | 2 x 1 ml | 60 EUR |
Dengue Control |
|||
ant-543 | ProSpec Tany | 100µg | 165 EUR |
Canine Control |
|||
MBS495203-1Set | MyBiosource | 1Set | 305 EUR |
Canine Control |
|||
MBS495203-5x1Set | MyBiosource | 5x1Set | 1390 EUR |
pTRIPZ control |
|||
PVTY00369 | Nova Lifetech | 2ug | 280 EUR |
NATtrol Strep A Negative Control (6 x 0.5mL) |
|||
NATSDG-6MC | Zeptometrix | 6 x 0.5mL | 221 EUR |
NATtrol Strep A Positive Control (6 x 0.5mL) |
|||
NATSPY-6MC | Zeptometrix | 6 x 0.5mL | 221 EUR |
Rat IgG-Biotin conjugate (isotype control) (Isotype control) |
|||
20005-B | Alpha Diagnostics | 100 ug | 196.8 EUR |
NATtrol CT/NG/TV Negative Control (6 x 1.0mL) |
|||
NATCTNGTV-NEG | Zeptometrix | 6 x 1.0mL | 97 EUR |
NATtrol CT/NG/TV Positive Control (6 x 1.0mL) |
|||
NATCTNGTV-POS | Zeptometrix | 6 x 1.0mL | 368 EUR |
Lectin binding native protein (positive control) |
|||
LBP18-N-1 | Alpha Diagnostics | 1 ml | 270 EUR |
Quality Control |
|||
abx098966-1vial | Abbexa | 1 vial | 360 EUR |
Ascites, Control |
|||
MBS652640-10mL | MyBiosource | 10mL | 415 EUR |
Ascites, Control |
|||
MBS652640-1mL | MyBiosource | 1mL | 190 EUR |
Ascites, Control |
|||
MBS652640-5x10mL | MyBiosource | 5x10mL | 1710 EUR |
Goat IgG (-ve control for flow cytometry) (isotype control) |
|||
20011-100 | Alpha Diagnostics | 100 test | 123.6 EUR |
Human IgD, Human Native Plasma (isotype control) |
|||
20007-8P-25 | Alpha Diagnostics | 25 ug | 343.2 EUR |
Control for Tyrosinase, 4 cases (1.5mm)HumanskinSkinIHC control |
|||
TYROSIN081 | Pantomics | 1.5mm | 50 EUR |
Negative Control |
|||
MBS2568128-1mL | MyBiosource | 1mL | 140 EUR |
Negative Control |
|||
MBS2568129-1mL | MyBiosource | 1mL | 135 EUR |
Positive Control |
|||
MBS2568130-1mL | MyBiosource | 1mL | 150 EUR |
Positive Control |
|||
MBS2568131-1mL | MyBiosource | 1mL | 150 EUR |
NATtrol MRSA/SA Negative Control (6 X 0.5 mL) |
|||
NATMSSE-6MC | Zeptometrix | 6 X 0.5 mL | 307 EUR |
NATtrol MRSA/SA Negative Control (6 X 0.5 mL) |
|||
NATMSSE-6MC-IVD | Zeptometrix | 6 X 0.5 mL | 327 EUR |
NATtrol MRSA/SA Negative Control (6 X 0.5 mL) |
|||
MDZ060 | Zeptometrix | 6 X 0.5 mL | 378.24 EUR |
PIPET CONTROLLER CONTROL BOARD |
|||
357484 | CORNING | 1/pk | 104.4 EUR |
Control siRNA Vector (pGB-control) |
|||
9500C-20 | Biovision | each | 405.6 EUR |
Mouse Parvovirus Native Antigen Positive Control |
|||
MBS412084-1mL | MyBiosource | 1mL | 175 EUR |
Mouse Parvovirus Native Antigen Positive Control |
|||
MBS412084-5x1mL | MyBiosource | 5x1mL | 645 EUR |
OOSA10387-100T - IgM NEGATIVE CONTROL Negative/Isotype Control |
|||
OOSA10387-100T | Aviva Systems Biology | 100Tests | 309 EUR |
OOSA10342-100UG - IgG1 NEGATIVE CONTROL Negative/Isotype Control |
|||
OOSA10342-100UG | Aviva Systems Biology | 0.1mg | 219 EUR |
OOSA10349-100T - IgG2a NEGATIVE CONTROL Negative/Isotype Control |
|||
OOSA10349-100T | Aviva Systems Biology | 100Tests | 299 EUR |
OOSA10380-100T - IgG2b NEGATIVE CONTROL Negative/Isotype Control |
|||
OOSA10380-100T | Aviva Systems Biology | 100Tests | 309 EUR |
OOSA10389-100T - IgG1 NEGATIVE CONTROL Negative/Isotype Control |
|||
OOSA10389-100T | Aviva Systems Biology | 100Tests | 309 EUR |
OOSA10397-100T - IgG2a NEGATIVE CONTROL Negative/Isotype Control |
|||
OOSA10397-100T | Aviva Systems Biology | 100Tests | 309 EUR |
NATtrol Influenza Negative Control (6 X 0.5 mL) |
|||
NATCXVA9-6MC | Zeptometrix | 6 X 0.5 mL | 220 EUR |
NATtrol Norovirus Negative Control (6 X 0.5 mL) |
|||
NATROTA-6MC-IVD | Zeptometrix | 6 X 0.5 mL | 223 EUR |
NATtrol T.vaginalis Negative Control (6 x 1.2 mL) |
|||
NATTVNEG-6MC | Zeptometrix | 6 x 1.2 mL | 348 EUR |
NATtrol T.vaginalis Positive Control (6 x 1.2 mL) |
|||
NATTVPOS-6MC | Zeptometrix | 6 x 1.2 mL | 348 EUR |
NATtrol Norovirus Negative Control (6 X 0.5 mL) |
|||
MDZ052 | Zeptometrix | 6 X 0.5 mL | 255.94 EUR |
CypExpress Control |
|||
MBS480553-10g | MyBiosource | 10g | 1905 EUR |
CypExpress Control |
|||
MBS480553-1g | MyBiosource | 1g | 320 EUR |
CypExpress Control |
|||
MBS480553-5x10g | MyBiosource | 5x10g | 8355 EUR |
CypExpress Control |
|||
MBS480553-5x1g | MyBiosource | 5x1g | 1220 EUR |
ODN 2088 control |
|||
tlrl-2088c-1 | InvivoGen FR | 1 mg | 546 EUR |
ODN 2395 control |
|||
tlrl-2395c-1 | InvivoGen FR | 1 mg | 546 EUR |
Control for Mammaglobin, 4 cases (1.5mm)HumanBreastBreastIHC control |
|||
MAMA-G081 | Pantomics | 1.5mm | 50 EUR |
NATtrol HSV 1 & 2 Positive Control (6 x 0.25 mL) |
|||
NATHSV-6L | Zeptometrix | 6 x 0.25 mL | 272 EUR |
Human IgE (Native, Plasma), purified (isotype control) |
|||
20007-3P | Alpha Diagnostics | 50 ug | 489.6 EUR |
Human IgA purified (native, Plasma) (isotype control) |
|||
20007-5-1 | Alpha Diagnostics | 1 mg | 196.8 EUR |
Human IgA purified (native, Plasma) (isotype control) |
|||
20007-5-5 | Alpha Diagnostics | 5 mg | 708 EUR |
SERION ELISA Avidity control Rubella Virus Avidity Control IgG |
|||
MBS191655-INQUIRE | MyBiosource | INQUIRE | Ask for price |
NATtrol CT/NG Negative Control Pack (6 X 1.25 mL) |
|||
NATCT/NGNEG-6MC-IVD | Zeptometrix | 6 X 1.25 mL | 240 EUR |
NATtrol CT/NG Negative Control Pack (6 X 1.25 mL) |
|||
MDZ004 | Zeptometrix | 6 X 1.25 mL | 299.62 EUR |
Control FD BNP |
|||
K023M-6 | Audit MicroControls | 6 x 1 mL | 292 EUR |
Control FD TDM |
|||
K068M-6 | Audit MicroControls | 6 x 5 mL | 205 EUR |
NATtrol Influenza/RSV Negative Control (6 x 0.5mL) |
|||
NATCXVA9-6C | Zeptometrix | 6 x 0.5mL | 220 EUR |
Control for GCDFP-15, 4 cases (1.5mm)HumanBreastBreastIHC control |
|||
GCDFP081 | Pantomics | 1.5mm | 50 EUR |
EDG-1 Control |
|||
BC-009 | Kamiya Biomedical Company | 100 uL | 350 EUR |
EDG-2 Control |
|||
BC-011 | Kamiya Biomedical Company | 100 uL | 350 EUR |
EDG-4 Control |
|||
BC-012 | Kamiya Biomedical Company | 100 uL | 350 EUR |
EDG-6 Control |
|||
BC-014 | Kamiya Biomedical Company | 100 uL | 350 EUR |
EDG-7 Control |
|||
BC-016 | Kamiya Biomedical Company | 100 uL | 350 EUR |
Rat Control IgG |
|||
AC034 | Abclonal | 100 ul | 159.6 EUR |
β-Gal Control |
|||
LV007 | ABM | 4 x 500 ul | 195 EUR |
NF-κB Control |
|||
T37559-10mg | TargetMol Chemicals | 10mg | Ask for price |
NF-κB Control |
|||
T37559-1g | TargetMol Chemicals | 1g | Ask for price |
NF-κB Control |
|||
T37559-1mg | TargetMol Chemicals | 1mg | Ask for price |
NF-κB Control |
|||
T37559-50mg | TargetMol Chemicals | 50mg | Ask for price |
NF-κB Control |
|||
T37559-5mg | TargetMol Chemicals | 5mg | Ask for price |
Rat Control IgG |
|||
MBS9144358-01mL | MyBiosource | 0.1mL | 140 EUR |
Rat Control IgG |
|||
MBS9144358-5x01mL | MyBiosource | 5x0.1mL | 465 EUR |
Rat Parvovirus (RPV), Native Antigen Positive Control |
|||
MBS412082-1mL | MyBiosource | 1mL | 175 EUR |
Rat Parvovirus (RPV), Native Antigen Positive Control |
|||
MBS412082-5x1mL | MyBiosource | 5x1mL | 645 EUR |
NATtrol Influenza/RSV Positive Control (6 x 0.25mL) |
|||
NATFLURSV-6L | Zeptometrix | 6 x 0.25mL | 272 EUR |
OOSA10361-1ML - Rat IgG2a NEGATIVE CONTROL Negative/Isotype Control |
|||
OOSA10361-1ML | Aviva Systems Biology | 1ml | 169 EUR |
SERION ELISA Avidity control Toxoplasma gondii Avidity Control IgG |
|||
MBS191654-INQUIRE | MyBiosource | INQUIRE | Ask for price |
Control for MSH2, 4 cases (1.5mm)HumanDigestive systemColonIHC control |
|||
MSH2081 | Pantomics | 1.5mm | 50 EUR |
Control for Olig2, 4 cases (1.5mm)HumanNervous systemBrainIHC control |
|||
OLIG2081 | Pantomics | 1.5mm | 50 EUR |
Tuttavia, lo studio di associazione pianificato sull’ampio genoma dei fenotipi di risposta e l’inclusione dei dati individuali di fenotipo e genotipo da questo studio nelle meta-analisi promettono di identificare in definitiva vulnerabilità e varianti protettive.